Kazuko Sakata
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Kazuko Sakata has a total of 43 co-authors. Here are the top co-authors by number of shared publications:
- Shanker Jha
School of Chemical and Biotechnology, SASTRA Deemed University, Thanjavur, India
4 shared publications Brittany E. Dong
Department of Pharmacology University of Tennessee Health Science Center Memphis TN USA
3 shared publicationsJanet Wang
Department of Pharmacology, College of Medicine, University of Tennessee Health Science Center, Memphis, USA
3 shared publicationsWilliam Schupp
Department of Pharmacology, College of Medicine, University of Tennessee Health Science Center, Memphis, USA
3 shared publications- Abigail E. Overacre-Delgoffe
Department of Immunology, University of Pittsburgh, Pittsburgh, PA, USA
2 shared publications - Sean M. Duke
Department of Neurology, Case Western Reserve University School of Medicine, University Hospitals Cleveland Medical Center, 10900 Euclid Ave., Cleveland, OH 44106, USA
2 shared publications
Latest Publications
- Open Access
- 8 September 2025
- Published by Springer Nature in Molecular Medicine
- Vol. 31 (1) , 1-4
Correction: Peripheral tissue BDNF expression is affected by promoter IV defect and enriched environments in mice: negative hippocampus-intestine and positive thymus-serum-muscle correlations
- 8 September 2025
- Published by Springer Nature in Molecular Medicine
- Vol. 31 (1) , 1-4
Open AccessCorrection: Peripheral tissue BDNF expression is affected by promoter IV defect and enriched environments in mice: negative hippocampus-intestine and positive thymus-serum-muscle correlations
- Open Access
Soluble β-Amyloid Oligomers Selectively Upregulate TRPC3 in Excitatory Neurons via Calcineurin-Coupled NFAT
To investigate how dysregulated transient receptor potential canonical channels (TRPCs) are associated with Alzheimer’s disease (AD), we challenged primary neurons with amyloid-β (Aβ). Both the naturally secreted or synthetic Aβ oligomers (AβOs) induced long-lasting increased TRPC3 and downregulated the TRPC6 expression in mature excitatory neurons (CaMKIIα-high) via a Ca2+-dependent calcineurin-coupled NFAT transcriptionally and calpain-mediated protein degradation, respectively. The TRPC3 expression was also found to be upregulated in pyramidal neurons of human AD brains. The selective downregulation of the Trpc6 gene induced synaptotoxicity, while no significant effect was observed from the Trpc3-targeting siRNA, suggesting potentially differential roles of TRPC3 and 6 in modulating the synaptic morphology and functions. Electrophysiological recordings of mouse hippocampal slices overexpressing TRPC3 revealed increased neuronal hyperactivity upon the TRPC3 channel activation by its agonist. Furthermore, the AβO-mediated synaptotoxicity appeared to be positively correlated with the degrees of the induced dendritic Ca2+ flux in neurons, which was completely prevented by the co-treatment with two pyrazole-based TRPC3-selective antagonists Pyr3 or Pyr10. Taken together, our findings suggest that the aberrantly upregulated TRPC3 is another ion channel critically contributing to the process of AβO-induced Ca2+ overload, neuronal hyperexcitation, and synaptotoxicity, thus representing a potential therapeutic target of AD.
Open AccessSoluble β-Amyloid Oligomers Selectively Upregulate TRPC3 in Excitatory Neurons via Calcineurin-Coupled NFAT
To investigate how dysregulated transient receptor potential canonical channels (TRPCs) are associated with Alzheimer’s disease (AD), we challenged primary neurons with amyloid-β (Aβ). Both the naturally secreted or synthetic Aβ oligomers (AβOs) induced long-lasting increased TRPC3 and downregulated the TRPC6 expression in mature excitatory neurons (CaMKIIα-high) via a Ca2+-dependent calcineurin-coupled NFAT transcriptionally and calpain-mediated protein degradation, respectively. The TRPC3 expression was also found to be upregulated in pyramidal neurons of human AD brains. The selective downregulation of the Trpc6 gene induced synaptotoxicity, while no significant effect was observed from the Trpc3-targeting siRNA, suggesting potentially differential roles of TRPC3 and 6 in modulating the synaptic morphology and functions. Electrophysiological recordings of mouse hippocampal slices overexpressing TRPC3 revealed increased neuronal hyperactivity upon the TRPC3 channel activation by its agonist. Furthermore, the AβO-mediated synaptotoxicity appeared to be positively correlated with the degrees of the induced dendritic Ca2+ flux in neurons, which was completely prevented by the co-treatment with two pyrazole-based TRPC3-selective antagonists Pyr3 or Pyr10. Taken together, our findings suggest that the aberrantly upregulated TRPC3 is another ion channel critically contributing to the process of AβO-induced Ca2+ overload, neuronal hyperexcitation, and synaptotoxicity, thus representing a potential therapeutic target of AD.
- Open Access
- 2 May 2025
- Published by Springer Nature in Molecular Medicine
- Vol. 31 (1) , 1-17
Peripheral tissue BDNF expression is affected by promoter IV defect and enriched environments in mice: negative hippocampus-intestine and positive thymus-serum-muscle correlations
Background: Brain-derived neurotrophic factor (BDNF) expression is reduced in the brain of various central nervous system (CNS) disorders, but its relation to peripheral expression remains unclear. This study aimed to determine peripheral BDNF expression affected by BDNF promoter IV defect and enriched environment treatment (EET). Promoter IV defect is associated with CNS disorders and chronic stress, whereas EET increases hippocampal BDNF expression and ameliorates CNS dysfunctions. Methods: Enzyme-linked immunosorbent assay measured BDNF protein levels in eleven regions (hippocampus, frontal cortex, heart, lung, liver, spleen, intestine, kidney, intestine, thymus, muscle, serum) in wild-type and knock-in promoter IV (KIV) mice with or without 3 weeks of EET provided after weaning. Results: Knock-in promoter IV resulted in BDNF levels significantly decreased in muscle, but significantly increased in intestine, liver, thymus, and serum, which suggests compensatory upregulation of other promoters in those tissues. EET increased BDNF levels in muscle and serum of KIV mice and thymus of wild-type mice, suggesting EET’s beneficial effects in muscle motor and adaptive immune regulation. EET increased hippocampal BDNF levels in both genotypes, which significantly negatively correlated with intestine BDNF levels, suggesting its role in the brain-gut axis. EET reduced wild-type heart BDNF levels, possibly through parasympathetic regulation. Significant positive BDNF correlations were observed among serum-muscle, serum-thymus, lung-spleen, and intestine-liver, suggesting inter-organ interaction and regulation of BDNF. Partial Least Squares discriminant analyses (PLS-DA) identified that variations in BDNF levels in intestine, liver, frontal cortex, and serum contribute most to classify promoter IV defect, and those in hippocampus, serum, heart, thymus, and liver contribute most to classify EET effects. Conclusion: This is the first study to demonstrate how genetic and environmental factors affect BDNF expression in peripheral tissues, highlighting the complex BDNF correlations across organ systems and suggesting usefulness of multivariate BDNF analyses for detecting promoter IV defect and enriched environment effects. Elucidation of BDNF’s role and regulatory mechanisms in peripheral organ systems may help better our understanding of its connection to CNS disorders and their treatments.
- 2 May 2025
- Published by Springer Nature in Molecular Medicine
- Vol. 31 (1) , 1-17
Open AccessPeripheral tissue BDNF expression is affected by promoter IV defect and enriched environments in mice: negative hippocampus-intestine and positive thymus-serum-muscle correlations
Background: Brain-derived neurotrophic factor (BDNF) expression is reduced in the brain of various central nervous system (CNS) disorders, but its relation to peripheral expression remains unclear. This study aimed to determine peripheral BDNF expression affected by BDNF promoter IV defect and enriched environment treatment (EET). Promoter IV defect is associated with CNS disorders and chronic stress, whereas EET increases hippocampal BDNF expression and ameliorates CNS dysfunctions. Methods: Enzyme-linked immunosorbent assay measured BDNF protein levels in eleven regions (hippocampus, frontal cortex, heart, lung, liver, spleen, intestine, kidney, intestine, thymus, muscle, serum) in wild-type and knock-in promoter IV (KIV) mice with or without 3 weeks of EET provided after weaning. Results: Knock-in promoter IV resulted in BDNF levels significantly decreased in muscle, but significantly increased in intestine, liver, thymus, and serum, which suggests compensatory upregulation of other promoters in those tissues. EET increased BDNF levels in muscle and serum of KIV mice and thymus of wild-type mice, suggesting EET’s beneficial effects in muscle motor and adaptive immune regulation. EET increased hippocampal BDNF levels in both genotypes, which significantly negatively correlated with intestine BDNF levels, suggesting its role in the brain-gut axis. EET reduced wild-type heart BDNF levels, possibly through parasympathetic regulation. Significant positive BDNF correlations were observed among serum-muscle, serum-thymus, lung-spleen, and intestine-liver, suggesting inter-organ interaction and regulation of BDNF. Partial Least Squares discriminant analyses (PLS-DA) identified that variations in BDNF levels in intestine, liver, frontal cortex, and serum contribute most to classify promoter IV defect, and those in hippocampus, serum, heart, thymus, and liver contribute most to classify EET effects. Conclusion: This is the first study to demonstrate how genetic and environmental factors affect BDNF expression in peripheral tissues, highlighting the complex BDNF correlations across organ systems and suggesting usefulness of multivariate BDNF analyses for detecting promoter IV defect and enriched environment effects. Elucidation of BDNF’s role and regulatory mechanisms in peripheral organ systems may help better our understanding of its connection to CNS disorders and their treatments.
- Open Access
- 9 October 2024
- Published by Springer Nature in Research Square
Peripheral tissue BDNF expression is affected by promoter IV defect and enriched environments in mice: negative hippocampus-intestine and positive thymus-serum-muscle correlations
Background: Brain-derived neurotrophic factor (BDNF) expression is reduced in the brain of various central nervous system (CNS) disorders, but its relation to peripheral expression remains unclear. This study aimed to determine peripheral BDNF expression affected by BDNF promoter IV defect and enriched environment treatment (EET). Promoter IV defect is associated with CNS disorders and chronic stress, whereas EET increases hippocampal BDNF expression and ameliorates CNS dysfunctions. Methods: Enzyme-linked immunosorbent assay was conducted to measure BDNF protein levels in eleven regions (hippocampus, frontal cortex, heart, lung, liver, spleen, intestine, kidney, intestine, thymus, muscle, serum) in wild-type and knock-in promoter IV (KIV) mice with or without 3 weeks of EET provided after weaning. Results: Knock-in promoter IV resulted in BDNF levels significantly decreased in muscle, but significantly increased in intestine, liver, thymus, and serum, which suggests compensatory upregulation of other promoters in those tissues. EET increased BDNF levels in muscle and serum of KIV mice and thymus of wild-type mice, along with significant positive serum-muscle and serum-thymus correlations of BDNF levels, suggesting EET’s beneficial effects in muscle motor and adaptive immune regulation. EET increased hippocampal BDNF levels in both genotypes and showed a significant negative correlation with intestine BDNF levels, suggesting its role in the brain-gut axis. EET reduced wild-type heart BDNF levels, possibly through parasympathetic regulation. BDNF levels were also significantly positively correlated between lung and spleen and between intestine and liver, suggesting inter-organ interaction and regulation of BDNF. Conclusion: This is the first study to not only demonstrate how these specific genetic and environmental factors affect BDNF expression in peripheral tissues, but also highlight the complex regulatory interplay of BDNF expression across organ systems. Elucidation of BDNF’s role and regulatory mechanisms in peripheral organ systems may help better our understanding of its connection to CNS disorders and their treatments.
- 9 October 2024
- Published by Springer Nature in Research Square
Open AccessPeripheral tissue BDNF expression is affected by promoter IV defect and enriched environments in mice: negative hippocampus-intestine and positive thymus-serum-muscle correlations
Background: Brain-derived neurotrophic factor (BDNF) expression is reduced in the brain of various central nervous system (CNS) disorders, but its relation to peripheral expression remains unclear. This study aimed to determine peripheral BDNF expression affected by BDNF promoter IV defect and enriched environment treatment (EET). Promoter IV defect is associated with CNS disorders and chronic stress, whereas EET increases hippocampal BDNF expression and ameliorates CNS dysfunctions. Methods: Enzyme-linked immunosorbent assay was conducted to measure BDNF protein levels in eleven regions (hippocampus, frontal cortex, heart, lung, liver, spleen, intestine, kidney, intestine, thymus, muscle, serum) in wild-type and knock-in promoter IV (KIV) mice with or without 3 weeks of EET provided after weaning. Results: Knock-in promoter IV resulted in BDNF levels significantly decreased in muscle, but significantly increased in intestine, liver, thymus, and serum, which suggests compensatory upregulation of other promoters in those tissues. EET increased BDNF levels in muscle and serum of KIV mice and thymus of wild-type mice, along with significant positive serum-muscle and serum-thymus correlations of BDNF levels, suggesting EET’s beneficial effects in muscle motor and adaptive immune regulation. EET increased hippocampal BDNF levels in both genotypes and showed a significant negative correlation with intestine BDNF levels, suggesting its role in the brain-gut axis. EET reduced wild-type heart BDNF levels, possibly through parasympathetic regulation. BDNF levels were also significantly positively correlated between lung and spleen and between intestine and liver, suggesting inter-organ interaction and regulation of BDNF. Conclusion: This is the first study to not only demonstrate how these specific genetic and environmental factors affect BDNF expression in peripheral tissues, but also highlight the complex regulatory interplay of BDNF expression across organ systems. Elucidation of BDNF’s role and regulatory mechanisms in peripheral organ systems may help better our understanding of its connection to CNS disorders and their treatments.
- 17 November 2022
- Published by Wiley in Journal of Neurochemistry
- Vol. 165 (2) , 131-148
Heat shock factor HSF1 regulates BDNF gene promoters upon acute stress in the hippocampus, together with pCREB
Heat shock factor 1 (HSF1) is a master stress‐responsive transcriptional factor, protecting cells from death. However, its gene regulation in vivo in the brain in response to neuronal stimuli remains elusive. Here, we investigated its direct regulation of the brain‐derived neurotrophic factor (BDNF) gene (Bdnf) in response to acute neuronal stress stimuli in the brain. The results of immunohistochemistry and chromatin immunoprecipitation quantitative PCR (ChIP‐qPCR) showed that administration of kainic acid (a glutamate receptor agonist inducing excitotoxity) to young adult mice induced HSF1 nuclear translocation and its binding to multiple Bdnf promoters in the hippocampus. Footshock, a physical stressor used for learning, also induced HSF1 binding to selected Bdnf promoters I and IV. This is, to our knowledge, the first demonstration of HSF1 gene regulation in response to neuronal stimuli in the hippocampus in vivo. HSF1 binding sites (HSEs) in Bdnf promoters I and IV were also detected when immunoprecipitated by an antibody of phosphorylated (p)CREB (cAMP‐responsive element‐binding protein), suggesting their possible interplay in acute stress‐induced Bdnf transcription. Interestingly, their promoter binding patterns differed by KA and footshock, suggesting that HSF1 and pCREB orchestrate to render fine‐tuned promoter control depending on the types of stress. Further, HSF1 overexpression increased Bdnf promoter activity in a luciferase assay, while virus infection of constitutively active‐form HSF1 increased levels of BDNF mRNA and protein in vitro in primary cultured neurons. These results indicated that HSF1 activation of Bdnf promoter was sufficient to induce BDNF expression. Taken together, these results suggest that HSF1 promoter‐specific control of Bdnf gene regulation plays an important role in neuronal protection and plasticity in the hippocampus in response to acute stress, possibly interplaying with pCREB. image
- 17 November 2022
- Published by Wiley in Journal of Neurochemistry
- Vol. 165 (2) , 131-148
Heat shock factor HSF1 regulates BDNF gene promoters upon acute stress in the hippocampus, together with pCREB
Heat shock factor 1 (HSF1) is a master stress‐responsive transcriptional factor, protecting cells from death. However, its gene regulation in vivo in the brain in response to neuronal stimuli remains elusive. Here, we investigated its direct regulation of the brain‐derived neurotrophic factor (BDNF) gene (Bdnf) in response to acute neuronal stress stimuli in the brain. The results of immunohistochemistry and chromatin immunoprecipitation quantitative PCR (ChIP‐qPCR) showed that administration of kainic acid (a glutamate receptor agonist inducing excitotoxity) to young adult mice induced HSF1 nuclear translocation and its binding to multiple Bdnf promoters in the hippocampus. Footshock, a physical stressor used for learning, also induced HSF1 binding to selected Bdnf promoters I and IV. This is, to our knowledge, the first demonstration of HSF1 gene regulation in response to neuronal stimuli in the hippocampus in vivo. HSF1 binding sites (HSEs) in Bdnf promoters I and IV were also detected when immunoprecipitated by an antibody of phosphorylated (p)CREB (cAMP‐responsive element‐binding protein), suggesting their possible interplay in acute stress‐induced Bdnf transcription. Interestingly, their promoter binding patterns differed by KA and footshock, suggesting that HSF1 and pCREB orchestrate to render fine‐tuned promoter control depending on the types of stress. Further, HSF1 overexpression increased Bdnf promoter activity in a luciferase assay, while virus infection of constitutively active‐form HSF1 increased levels of BDNF mRNA and protein in vitro in primary cultured neurons. These results indicated that HSF1 activation of Bdnf promoter was sufficient to induce BDNF expression. Taken together, these results suggest that HSF1 promoter‐specific control of Bdnf gene regulation plays an important role in neuronal protection and plasticity in the hippocampus in response to acute stress, possibly interplaying with pCREB. image
- 18 June 2021
- Published by Elsevier in Neurochemistry International
- Vol. 148, 105104
ER stress associated TXNIP-NLRP3 inflammasome activation in hippocampus of human Alzheimer's disease
- 18 June 2021
- Published by Elsevier in Neurochemistry International
- Vol. 148, 105104
ER stress associated TXNIP-NLRP3 inflammasome activation in hippocampus of human Alzheimer's disease
- 12 June 2020
- Published by Wiley in Journal of Neurochemistry
- Vol. 154 (1) , 41-55
BDNF deficiency and enriched environment treatment affect neurotransmitter gene expression differently across ages
Deficiency of activity‐induced expression of brain‐derived neurotrophic factor (BDNF) disturbs neurotransmitter gene expression. Enriched environment treatment (EET) ameliorates the defects. However, how BDNF deficiency and EET affect the neurotransmitter gene expression differently across ages remains unclear. We addressed this question by determining the neurotransmitter gene expression across three life stages in wild‐type and activity‐dependent BDNF‐deficient (KIV) mice. Mice received 2‐months of standard control treatment (SCT) or EET at early‐life development (ED: 0–2 months), young adulthood (2–4 months), and old adulthood (12–14 months) (N = 16/group). Half of these mice received additional 1‐month SCT to examine persisting EET effects. High‐throughput quantitative reverse transcription polymerase chain reaction measured expression of 81 genes for dopamine, adrenaline, serotonin, gamma aminobutyric acid, glutamate, acetylcholine, and BDNF systems in the frontal cortex (FC) and hippocampus. Results revealed that BDNF deficiency mostly reduced neurotransmitter gene expression, greatest at ED in the FC. EET increased expression of a larger number of genes at ED than adulthood, particularly in the KIV FC. Many genes down‐regulated in KIV mice were up‐regulated by EET, which persisted when EET was provided at ED (e.g., 5‐hydroxytryptamine (serotonin) transporter [5HTT], ADRA1D, GRIA3, GABRA5, GABBR2). In both the regions, BDNF deficiency decreased the density of gene co‐expression network specifically at ED, while EET increased the density and hub genes (e.g., GAT1, GABRG3, GRIN1, CHRNA7). These results suggest that BDNF deficiency, which occurs under chronic stress, causes neurotransmitter dysregulations prominently at ED, particularly in the FC. EET at ED may be most effective to normalize the dysregulations, providing persisting effects later in life.OPEN SCIENCE BADGES: This article has received a badge for *Open Materials* because it provided all relevant information to reproduce the study in the manuscript. More information about the Open Science badges can be found at https://cos.io/our-services/open-science-badges/. image
- 12 June 2020
- Published by Wiley in Journal of Neurochemistry
- Vol. 154 (1) , 41-55
BDNF deficiency and enriched environment treatment affect neurotransmitter gene expression differently across ages
Deficiency of activity‐induced expression of brain‐derived neurotrophic factor (BDNF) disturbs neurotransmitter gene expression. Enriched environment treatment (EET) ameliorates the defects. However, how BDNF deficiency and EET affect the neurotransmitter gene expression differently across ages remains unclear. We addressed this question by determining the neurotransmitter gene expression across three life stages in wild‐type and activity‐dependent BDNF‐deficient (KIV) mice. Mice received 2‐months of standard control treatment (SCT) or EET at early‐life development (ED: 0–2 months), young adulthood (2–4 months), and old adulthood (12–14 months) (N = 16/group). Half of these mice received additional 1‐month SCT to examine persisting EET effects. High‐throughput quantitative reverse transcription polymerase chain reaction measured expression of 81 genes for dopamine, adrenaline, serotonin, gamma aminobutyric acid, glutamate, acetylcholine, and BDNF systems in the frontal cortex (FC) and hippocampus. Results revealed that BDNF deficiency mostly reduced neurotransmitter gene expression, greatest at ED in the FC. EET increased expression of a larger number of genes at ED than adulthood, particularly in the KIV FC. Many genes down‐regulated in KIV mice were up‐regulated by EET, which persisted when EET was provided at ED (e.g., 5‐hydroxytryptamine (serotonin) transporter [5HTT], ADRA1D, GRIA3, GABRA5, GABBR2). In both the regions, BDNF deficiency decreased the density of gene co‐expression network specifically at ED, while EET increased the density and hub genes (e.g., GAT1, GABRG3, GRIN1, CHRNA7). These results suggest that BDNF deficiency, which occurs under chronic stress, causes neurotransmitter dysregulations prominently at ED, particularly in the FC. EET at ED may be most effective to normalize the dysregulations, providing persisting effects later in life.OPEN SCIENCE BADGES: This article has received a badge for *Open Materials* because it provided all relevant information to reproduce the study in the manuscript. More information about the Open Science badges can be found at https://cos.io/our-services/open-science-badges/. image
- 31 May 2018
- Published by Wiley in Genes, Brain and Behavior
- Vol. 17 (8) , e12485
The effect of enriched environment across ages: A study of anhedonia and BDNF gene induction
Enriched environment treatment (EET) is a potential intervention for depression by inducing brain‐derived neurotrophic factor (BDNF). However, its age dependency remains unclear. We recently found that EET during early‐life development (ED) was effective in increasing exploratory activity and anti‐despair behavior, particularly in promoter IV‐driven BDNF deficient mice (KIV), with the largest BDNF protein induction in the hippocampus and frontal cortex. Here, we further determined age dependency of EET effects on anhedonia and promoter‐specific BDNF transcription, by using the sucrose preference test and qRT‐PCR. Wild‐type (WT) and KIV mice received 2 months of EET during ED, young‐adulthood and old‐adulthood (0‐2, 2‐4 and 12‐14 months, respectively). All KIV groups showed reduced sucrose preference, which EET equally reversed regardless of age. EET increased hippocampal BDNF mRNA levels for all ages and genotypes, but increased frontal cortex BDNF mRNA levels only in ED KIV and old WT mice. Transcription by promoters I and IV was age‐dependent in the hippocampus of WT mice: more effective induction of exon IV or I during ED or old‐adulthood, respectively. Transcription by almost all 9 promoters was age‐specific in the frontal cortex, mostly observed in ED KIV mice. After discontinuance of EET, the EET effects on anti‐anhedonia and BDNF transcription in both regions persisted only in ED KIV mice. These results suggested that EET was equally effective in reversing anhedonia and inducing hippocampal BDNF transcription, but was more effective during ED in inducing frontal cortex BDNF transcription and for lasting anti‐anhedonic and BDNF effects particularly in promoter IV‐BDNF deficiency.
- 31 May 2018
- Published by Wiley in Genes, Brain and Behavior
- Vol. 17 (8) , e12485
The effect of enriched environment across ages: A study of anhedonia and BDNF gene induction
Enriched environment treatment (EET) is a potential intervention for depression by inducing brain‐derived neurotrophic factor (BDNF). However, its age dependency remains unclear. We recently found that EET during early‐life development (ED) was effective in increasing exploratory activity and anti‐despair behavior, particularly in promoter IV‐driven BDNF deficient mice (KIV), with the largest BDNF protein induction in the hippocampus and frontal cortex. Here, we further determined age dependency of EET effects on anhedonia and promoter‐specific BDNF transcription, by using the sucrose preference test and qRT‐PCR. Wild‐type (WT) and KIV mice received 2 months of EET during ED, young‐adulthood and old‐adulthood (0‐2, 2‐4 and 12‐14 months, respectively). All KIV groups showed reduced sucrose preference, which EET equally reversed regardless of age. EET increased hippocampal BDNF mRNA levels for all ages and genotypes, but increased frontal cortex BDNF mRNA levels only in ED KIV and old WT mice. Transcription by promoters I and IV was age‐dependent in the hippocampus of WT mice: more effective induction of exon IV or I during ED or old‐adulthood, respectively. Transcription by almost all 9 promoters was age‐specific in the frontal cortex, mostly observed in ED KIV mice. After discontinuance of EET, the EET effects on anti‐anhedonia and BDNF transcription in both regions persisted only in ED KIV mice. These results suggested that EET was equally effective in reversing anhedonia and inducing hippocampal BDNF transcription, but was more effective during ED in inducing frontal cortex BDNF transcription and for lasting anti‐anhedonic and BDNF effects particularly in promoter IV‐BDNF deficiency.
- Open Access
- 19 July 2017
- Published by Wiley in Journal of Neurochemistry
- Vol. 143 (1) , 49-64
PromoterIV‐BDNFdeficiency disturbs cholinergic gene expression ofCHRNA5,CHRM2, andCHRM5: effects of drug and environmental treatments
Brain‐derived neurotrophic factor (BDNF) promotes maturation of cholinergic neurons. However, how activity‐dependentBDNFexpression affects specific cholinergic gene expression remains unclear. This study addressed this question by determiningmRNAlevels of 22 acetylcholine receptor subunits, the choline transporter (CHT), and the choline acetyltransferase (ChAT) in mice deficient in activity‐dependentBDNFvia promoterIV(KIV) and control wild‐type mice. QuantitativeRT‐PCRrevealed significant reductions in nicotinic acetylcholine receptor alpha 5 (CHRNA5) in the frontal cortex and hippocampus and M5 muscarinic acetylcholine receptor (CHRM5) in the hippocampus, but significant increases in M2 muscarinic acetylcholine receptor (CHRM2) in the frontal cortex ofKIVmice compared to wild‐type mice. Three‐week treatments with fluoxetine, phenelzine, duloxetine, imipramine, or an enriched environment treatment (EET) did not affect the altered expression of these genes except thatEETincreasedCHRNA5 levels only inKIVfrontal cortex.EETalso increased levels ofCHRNA7,CHT, and ChAT, again only in theKIVfrontal cortex. The imipramine treatment was most prominent among the four antidepressants; it up‐regulated hippocampalCHRM2 and frontal cortexCHRM5 in both genotypes, and frontal cortexCHRNA7 only inKIVmice. To the best of our knowledge, this is the first evidence thatBDNFdeficiency disturbs expression ofCHRNA5,CHRM2, andCHRM5. Our results suggest that promoterIV‐BDNFdeficiency – which occurs under chronic stress – causes cholinergic dysfunctions via these receptors.EETis effective onCHRNA5, while its compensatory induction of other cholinergic genes or drugs targetingCHRNA5,CHRM2, andCHRM5 may become an alternative strategy to reverse theseBDNF‐linked cholinergic dysfunctions. image
- 19 July 2017
- Published by Wiley in Journal of Neurochemistry
- Vol. 143 (1) , 49-64
Open AccessPromoterIV‐BDNFdeficiency disturbs cholinergic gene expression ofCHRNA5,CHRM2, andCHRM5: effects of drug and environmental treatments
Brain‐derived neurotrophic factor (BDNF) promotes maturation of cholinergic neurons. However, how activity‐dependentBDNFexpression affects specific cholinergic gene expression remains unclear. This study addressed this question by determiningmRNAlevels of 22 acetylcholine receptor subunits, the choline transporter (CHT), and the choline acetyltransferase (ChAT) in mice deficient in activity‐dependentBDNFvia promoterIV(KIV) and control wild‐type mice. QuantitativeRT‐PCRrevealed significant reductions in nicotinic acetylcholine receptor alpha 5 (CHRNA5) in the frontal cortex and hippocampus and M5 muscarinic acetylcholine receptor (CHRM5) in the hippocampus, but significant increases in M2 muscarinic acetylcholine receptor (CHRM2) in the frontal cortex ofKIVmice compared to wild‐type mice. Three‐week treatments with fluoxetine, phenelzine, duloxetine, imipramine, or an enriched environment treatment (EET) did not affect the altered expression of these genes except thatEETincreasedCHRNA5 levels only inKIVfrontal cortex.EETalso increased levels ofCHRNA7,CHT, and ChAT, again only in theKIVfrontal cortex. The imipramine treatment was most prominent among the four antidepressants; it up‐regulated hippocampalCHRM2 and frontal cortexCHRM5 in both genotypes, and frontal cortexCHRNA7 only inKIVmice. To the best of our knowledge, this is the first evidence thatBDNFdeficiency disturbs expression ofCHRNA5,CHRM2, andCHRM5. Our results suggest that promoterIV‐BDNFdeficiency – which occurs under chronic stress – causes cholinergic dysfunctions via these receptors.EETis effective onCHRNA5, while its compensatory induction of other cholinergic genes or drugs targetingCHRNA5,CHRM2, andCHRM5 may become an alternative strategy to reverse theseBDNF‐linked cholinergic dysfunctions. image
- Open Access
- 20 September 2016
- Published by Springer Nature in Translational Psychiatry
- Vol. 6 (9) , e896
Antidepressive and BDNF effects of enriched environment treatment across ages in mice lacking BDNF expression through promoter IV
Reduced promoter IV-driven expression of brain-derived neurotrophic factor (BDNF) is implicated in stress and major depression. We previously reported that defective promoter IV (KIV) caused depression-like behavior in young adult mice, which was reversed more effectively by enriched environment treatment (EET) than antidepressants. The effects of promoter IV-BDNF deficiency and EET over the life stages remain unknown. Since early-life development (ED) involves dynamic epigenetic processes, we hypothesized that EET during ED would provide maximum antidepressive effects that would persist later in life due to enhanced, long-lasting BDNF induction. We tested this hypothesis by determining EET effects across three life stages: ED (0–2 months), young adult (2–4 months), and old adult (12–14 months). KIV mice at all life stages showed depression-like behavior in the open-field and tail-suspension tests compared with wild-type mice. Two months of EET reduced depression-like behavior in ED and young adult, but not old adult mice, with the largest effect in ED KIV mice. This effect lasted for 1 month after discontinuance of EET only in ED mice. BDNF protein induction by EET in the hippocampus and frontal cortex was also the largest in ED mice and persisted only in the hippocampus of ED KIV mice after discontinuance of EET. No gender-specific effects were observed. The results suggest that defective promoter IV causes depression-like behavior, regardless of age and gender, and that EET during ED is particularly beneficial to individuals with promoter IV-BDNF deficiency, while additional treatment may be needed for older adults.
- 20 September 2016
- Published by Springer Nature in Translational Psychiatry
- Vol. 6 (9) , e896
Open AccessAntidepressive and BDNF effects of enriched environment treatment across ages in mice lacking BDNF expression through promoter IV
Reduced promoter IV-driven expression of brain-derived neurotrophic factor (BDNF) is implicated in stress and major depression. We previously reported that defective promoter IV (KIV) caused depression-like behavior in young adult mice, which was reversed more effectively by enriched environment treatment (EET) than antidepressants. The effects of promoter IV-BDNF deficiency and EET over the life stages remain unknown. Since early-life development (ED) involves dynamic epigenetic processes, we hypothesized that EET during ED would provide maximum antidepressive effects that would persist later in life due to enhanced, long-lasting BDNF induction. We tested this hypothesis by determining EET effects across three life stages: ED (0–2 months), young adult (2–4 months), and old adult (12–14 months). KIV mice at all life stages showed depression-like behavior in the open-field and tail-suspension tests compared with wild-type mice. Two months of EET reduced depression-like behavior in ED and young adult, but not old adult mice, with the largest effect in ED KIV mice. This effect lasted for 1 month after discontinuance of EET only in ED mice. BDNF protein induction by EET in the hippocampus and frontal cortex was also the largest in ED mice and persisted only in the hippocampus of ED KIV mice after discontinuance of EET. No gender-specific effects were observed. The results suggest that defective promoter IV causes depression-like behavior, regardless of age and gender, and that EET during ED is particularly beneficial to individuals with promoter IV-BDNF deficiency, while additional treatment may be needed for older adults.